Feedback secures funding to extend Oldham CDC pilot

Clinical infrastructure specialist Feedback announced the securing of further funding on Monday, to extend its Community Diagnostic Centre (CDC) pathway pilot at the Northern Care Alliance NHS Foundation Trust (NCA) site in Oldham.

  • Feedback
  • 02 September 2024 12:18:36
Feedback

Source: Sharecast

The AIM-traded firm said the additional funding, totalling £69,000, would support the continuation of the pilot through to 31 March 2025.

It said the funding came from the 2024-2025 NHS England budget, with an initial 50% already allocated from the first half budget, covering the period up to 30 September.

The remaining balance was expected from the second half budget.

Feedback said the pilot, focusing on breathlessness, aimed to demonstrate the effectiveness of a pathway approach in improving CDC utilisation and reducing patient wait times, contributing valuable data to support further expansion and funding.

Additionally, the use of Feedback’s Bleepa digital referral system at the NCA had significantly expanded since December.

Initially supporting six specialities at Oldham and one at Fairfield General Hospital, the system now covered 11 specialities at Oldham, including endocrinology and haematology, and five at Fairfield, including cardiology and respiratory.

The board said the number of users increased by 68% between June 2023 and June 2024, with over 1,400 users generating more than 9,200 patient referrals in the period.

A report by Unity Insights, published in October last year, highlighted that NCA experienced a dramatic reduction in clinical response times after switching from paper-based to Bleepa digital referrals.

The report estimated that the time savings could be worth £0.82m to the NCA over five years, with potential savings of £7.7m if the system were adopted across the Greater Manchester Integrated Care Board.

“We are extremely pleased to announce the confirmation of the funded second stage of our CDC pilot at Oldham and remain focussed on delivering further evidence that supports the adoption of a pathway approach for CDCs, enabled by the Bleepa platform,” said chief executive officer Tom Oakley.

“We see this as further validation of the value the NCA and NHSE sees in our service and will use our findings to support national expansion.

“As use of our digital inpatient referral system expands to cover more specialities, more users and capture more referrals at Oldham and Fairfield, we are eager to build upon the positive findings from Unity's report and deliver much needed time savings to the NHS.”

At 0821 BST, shares in Feedback were up 1.62% at 55.89p.

Reporting by Josh White for Sharecast.com.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Lloyds and Lloyds Bank are trading names of Halifax Share Dealing Limited. The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.